Literature DB >> 26251329

RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial.

Lavanniya K Palani Velu1, Colin W Steele1, Euan J Dickson1, C Ross Carter1, Colin J McKay1, Paul G Horgan1, Donald C McMillan1, Nigel B Jamieson2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26251329      PMCID： PMC4836817          DOI： 10.1093/jnci/djv204

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

1.  Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.

Authors:  Simon M Denley; Nigel B Jamieson; Pamela McCall; Karin A Oien; Jennifer P Morton; C Ross Carter; Joanne Edwards; Colin J McKay
Journal:  J Gastrointest Surg       Date:  2013-02-23       Impact factor: 3.452

2.  nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

Authors:  David Goldstein; Robert Hassan El-Maraghi; Pascal Hammel; Volker Heinemann; Volker Kunzmann; Javier Sastre; Werner Scheithauer; Salvatore Siena; Josep Tabernero; Luis Teixeira; Giampaolo Tortora; Jean-Luc Van Laethem; Rosemary Young; Darryl Neil Penenberg; Brian Lu; Alfredo Romano; Daniel D Von Hoff
Journal:  J Natl Cancer Inst       Date:  2015-01-31       Impact factor: 13.506

3.  A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma.

Authors:  Nigel B Jamieson; Simon M Denley; Jennifer Logue; Douglas J MacKenzie; Alan K Foulis; Euan J Dickson; Clem W Imrie; Ross Carter; Colin J McKay; Donald C McMillan
Journal:  Ann Surg Oncol       Date:  2011-01-26       Impact factor: 5.344

4.  A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study.

Authors:  Michael J Proctor; David S Morrison; Dinesh Talwar; Steven M Balmer; Colin D Fletcher; Denis St J O'Reilly; Alan K Foulis; Paul G Horgan; Donald C McMillan
Journal:  Eur J Cancer       Date:  2011-07-01       Impact factor: 9.162

Review 5.  Genomic medicine frontier in human solid tumors: prospects and challenges.

Authors:  Rodrigo Dienstmann; Jordi Rodon; Jordi Barretina; Josep Tabernero
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

6.  Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.

Authors:  R Alvarez; M Musteanu; E Garcia-Garcia; P P Lopez-Casas; D Megias; C Guerra; M Muñoz; Y Quijano; A Cubillo; J Rodriguez-Pascual; C Plaza; E de Vicente; S Prados; S Tabernero; M Barbacid; F Lopez-Rios; M Hidalgo
Journal:  Br J Cancer       Date:  2013-08-01       Impact factor: 7.640
  6 in total
  1 in total

1.  An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.

Authors:  Xiang Ling; Wenjie Wu; Chuandong Fan; Chao Xu; Jianqun Liao; Laurie J Rich; Ruea-Yea Huang; Elizabeth A Repasky; Xinjiang Wang; Fengzhi Li
Journal:  J Exp Clin Cancer Res       Date:  2018-10-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.